Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study
Main finding · eGFR changeResult — go to the resultDifference 8.0 95% CI 5.7–10.4Authors' conclusion
In this Chinese real-world study of patients with T2DM, treatment with SGLT2 inhibitors was associated with a slower decline in kidney function compared with other glucose-lowering drugs.
Study context
- Population
- Adults ≥18 years with T2D for ≥12 months, 45 hospitals in China; baseline mean HbA1c 8.33%, mean eGFR 114.68 mL/min/1.73 m²5,562 completed 6 months
- Exposure
- SGLT2i vs other glucose-lowering drugs
- Outcome
- Rate of change of eGFR from baseline
- Follow-up
- 6 months
Methodological detailsmulticentre, observational, real-world, September 2021 to September 2023
- Multicentre
- Observational
- Real-world
- September 2021 to September 2023
Main finding
eGFR change
Difference
8.0
95% CI 5.7–10.4
P < 0.0001
Change by group
SGLT2 inhibitors
+1.2
mean · mL/min/1.73 m²
Controls
−6.0
mean · mL/min/1.73 m²
SGLT2 inhibitorsvs Controls
difference 8.0 (95% CI 5.7–10.4); P < 0.0001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2 inhibitors | Controls | RR (95% CI) | |
|---|---|---|---|---|
| eGFR decline ≥25% · 6 months | 18.9% | 22.8% | 0.83 (0.78–0.87) | |
| Composite: improved glycaemic control plus stable renal function · 6 months | 1.12 (1.06–1.18) | |||
| 0.512Relative risk (log scale) |
Original publication
Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study. Diabetes Obes Metab. Published 28 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →